Skin changes on continued imatinib therapy in patients with Ph+ CML

被引：0
|
作者：
Saikia, Tapan [1 ]
Hazarika, Nandim [1 ]
Dhabhar, Boman [1 ]
机构：
[1] Prince Aly Khan Hosp, Bombay, Maharashtra, India
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.2963.2963
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2963
引用
收藏
页码：870A / 870A
页数：1
相关论文
共 50 条
  • [21] INVITRO GROWTH OF PH+ BASOPHILS IN ACUTE PHASE OF CML
    DENEGRI, JF
    NAIMAN, SC
    JIRIK, FR
    THOMAS, JW
    BLOOD, 1977, 50 (05) : 144 - 144
  • [22] Evaluation of efficiency of imatinib therapy in patients with CML in chronic phase therapy
    Ter-Grigoryan, A.
    Melkikyan, N.
    Daghbashyan, S.
    Sahakyan, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 59 - 59
  • [23] Efficacy of nilotinib in a young patient with high Sokal risk CML Ph+ in treatment failure after high dose imatinib
    Russo, Sabina
    Penna, Giuseppa
    D'Angelo, Arianna
    Allegra, Alessandro
    Alonci, Andrea
    Musolino, Caterina
    CLINICAL MANAGEMENT ISSUES, 2011, 5 : 7 - 14
  • [24] What is the best salvage therapy for treatment of isolated CNS relapse in elderly patients with imatinib-responsive Ph+ ALL?
    Mele, Giuseppe
    Pinna, Salvatore
    Melpignano, Angela
    Romano, Antonio
    Brocca, Maurizio Claudio
    Coppi, Maria Rosaria
    Quarta, Giovanni
    LEUKEMIA RESEARCH, 2007, 31 (10) : 1445 - 1447
  • [25] PH+ CML WITH 7Q- AND PROLONGED CHRONIC PHASE
    ZHONG, C
    MORGAN, R
    SANDBERG, AA
    SCHEERER, PP
    CANCER GENETICS AND CYTOGENETICS, 1992, 58 (02) : 212 - 213
  • [26] Potential therapy for Ph1-ALL and CML tumors unresponsive to imatinib and/or dasatinib
    Nature Clinical Practice Oncology, 2008, 5 (1): : 6 - 6
  • [27] Experience with imatinib mesylate in children with Ph+ chronic myelogenous leukemia
    Kapoor, Gauri
    Abedin, Sarfrazu
    Garg, Pravesh
    Tyagi, Vinod
    Khullar, Paras
    PEDIATRIC BLOOD & CANCER, 2007, 49 (04) : 528 - 528
  • [28] Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib
    Giles, Francis J.
    Larson, Richard A.
    Kantarjian, Hagop M.
    le Coutre, Philipp
    Baccarani, Michele
    Haque, Ariful
    Gallagher, Neil
    Ottmann, Oliver G.
    BLOOD, 2007, 110 (11) : 310A - 310A
  • [29] The effect of Gleevec (STI571;imatinib mesylate) in patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) with secondary chromosomal aberrations.
    Mohamed, AN
    Pemberton, P
    Zonder, JA
    Homisha, S
    Ford, J
    Schiffer, CA
    BLOOD, 2001, 98 (11) : 560A - 560A
  • [30] A prospective study in Ph+ CML patients:: Fish is effectiveas conventional cytogenetics for definition of cytogenetic response to imatinib.: Correlation with molecular response (a GIMEMA WP analysis)
    Marzocchi, G.
    Luatti, S.
    Amabile, M.
    Gamberini, C.
    Baldazzi, C.
    Stacchini, M.
    Iacobucci, I.
    Mancini, M.
    Cuneo, A.
    Specchia, G.
    Kerim, S.
    Giugliano, E.
    Giussani, U.
    Grimoldi, M. G.
    Abruzzese, E.
    Mecucci, C.
    Bernasconi, P.
    Gozzetti, A.
    Palka, G.
    Zanatta, L.
    Zaccaria, A.
    Castagnetti, F.
    Martinelli, G.
    Rosti, G.
    Baccarani, M.
    Testoni, N.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 45 - 45
12345